HCPCS
J9144
1 billing unit = 10 mg
Darzalex Faspro and its IV counterpart
Faspro and Darzalex are the same monoclonal antibody in two products with different everything else: J-code, NDC, vial, dose model, administration code and chair time. J9144 pays $17.255 less per 10 mg than J9145, but the labeled Faspro dose is flat while the IV dose is weight-based, so which product allows more depends on the patient’s weight.
| HCPCS | Rate/10 mg | Dose (80 kg) | Drug allowed | Administration | Visit total | |
|---|---|---|---|---|---|---|
| Darzalex Faspro (SC) | J9144 | $57.973 | 1,800 mg flat | $10,435.14 | $71.81 (96401) | $10,506.95 |
| Darzalex (IV) | J9145 | $75.228 | 1,280 mg (16 mg/kg) | $9,629.18 | $218.44 (96413 + 3×96415) | $9,847.62 |
At 80 kg, Faspro’s flat 1,800 mg visit allows $659.33 more than the IV visit’s 1,280 mg (16 mg/kg) dose plus a 3-to-4-hour infusion. Faspro’s first-hour IV comparison runs longer still: a first IV dose split over about 7 hours (96413 + 6×96415 = $303.61) brings the IV visit to $9,932.79, $574.16 less than Faspro. Say both halves: Faspro is more per visit at 80 kg, and it is a 5-minute injection instead of 3 to 7 hours in the chair.
Faspro vs. IV Darzalex — the crossover weight
IV Darzalex is weight-based (16 mg/kg); Faspro is flat (1,800 mg every dose, regardless of weight). Because one side of the comparison moves with weight and the other does not, there is a crossover point: above about 85 kg, the IV visit’s drug allowance passes Faspro’s $10,506.95 and the injection becomes the cheaper visit (($10,506.95 − $218.44) ÷ $120.36 per kg ≈ 85 kg, using J9145’s $7.523/mg and the 96413+3×96415 administration allowance).
Every billing axis differs between the two products: J-code, NDC, vial size, dose model and administration code. Confirm which formulation the encounter note describes before coding the claim — a flat 180 units is never the right answer for an IV Darzalex claim, and a weight-based unit count is never right for Faspro.
Darzalex Faspro dosing, workup and duration
Every dose is the identical 1,800 mg subcutaneous injection. What a biller needs to confirm is not the dose — it never changes — but which of six labeled schedules the regimen follows, because the interval between doses shifts partway through several of them.
| Regimen | Schedule | Notes |
|---|---|---|
| Multiple myeloma — 4-week regimens (with lenalidomide, pomalidomide or carfilzomib plus dexamethasone) and monotherapy | Label Table 1: 1,800 mg subcutaneous over 3 to 5 minutes; weekly x 8, every 2 weeks x 8, then every 4 weeks | The most common schedule: 23 doses in the first year (8 + 8 + 7), 13 a year after that. Every dose is one 15 mL vial, 180 billing units and one 96401 line. |
| Multiple myeloma — with bortezomib, melphalan and prednisone (6-week cycle) | Label Table 2: weekly x 6, every 3 weeks x 16, then every 4 weeks | 22 doses in the first year on this schedule (6 + 16); the every-4-week phase starts in year two. |
| Multiple myeloma — with bortezomib, thalidomide or lenalidomide, and dexamethasone, around transplant (4-week cycle) | Label Tables 3 and 4: weekly x 8, every 2 weeks x 4, transplant, then every 2 weeks x 4 in consolidation | The only schedule with a planned gap; the dose and the units per dose do not change. |
| Multiple myeloma — with bortezomib and dexamethasone, or bortezomib, lenalidomide and dexamethasone (3-week cycle) | Label Tables 5 and 6: weekly, then every 3 weeks to week 24, then every 4 weeks | Same 1,800 mg vial and 180 units every visit; only the calendar differs. |
| High-risk smoldering multiple myeloma — monotherapy (4-week cycle) | Label Table 7: weekly x 8, every 2 weeks x 8, then every 4 weeks, capped at 39 cycles | Same calendar as the 4-week regimens, with a ceiling on the number of cycles. |
| Light chain (AL) amyloidosis — with bortezomib, cyclophosphamide and dexamethasone (4-week cycle) | Label Table 8: weekly x 8, every 2 weeks x 8, then every 4 weeks, up to 2 years | The AL amyloidosis indication carries its own cardiac-toxicity warning (label 5.2) and bills under E85.81, not a C90 code. |
Pre-treatment workup checklist
- Pre-medicate 1 to 3 hours before every dose with a corticosteroid, acetaminophen and a histamine-1 antagonist, and give the post-injection corticosteroid the label sets — each billed on its own line.
- Type and screen the patient before the first dose: daratumumab binds CD38 on red cells and interferes with indirect antiglobulin tests for up to 6 months after the last dose.
- For the AL amyloidosis indication, assess cardiac status before starting; serious or fatal cardiac reactions occurred in patients with cardiac involvement.
- Confirm the regimen before the first claim: the same 1,800 mg vial and 180 units bill every visit, but the calendar between doses follows the regimen table the prescriber chose.
A schedule that changes shape, not a repeating interval
Five of the six regimens open with a weekly phase, step down to every 2, 3 or 4 weeks, and continue until progression — so a single prior authorization or claim history can show three different intervals for the same drug and dose over one year. The 4-week regimens and monotherapy total 23 doses in year one (8 weekly, 8 every 2 weeks, 7 every 4 weeks) and 13 a year after that.
Need the billing units for a patient? Convert dose to J9144 billing units →
Darzalex Faspro billing reference
HCPCS
J9144 — “Inj daratumumab hyal,” 10 mg per billing unit. A 1,800 mg dose is 180 units, never 1,800 — the tenfold trap on this drug.
NDC
NDC 57894-503-01, Janssen Biotech.
| NDC (10-digit) | Package |
|---|---|
57894-503-01 | 1,800 mg daratumumab with 30,000 units hyaluronidase-fihj in 15 mL, single-dose vial |
Administration — a single code, no split
96401 pays $71.81 for the 3-to-5-minute subcutaneous injection. Unlike some subcutaneous anti-neoplastics, Faspro carries no competing lower-paying code — there is no 96372 argument on this product.
| CPT | Description | Use for |
|---|---|---|
96401 | Chemotherapy administration, SC/IM; non-hormonal anti-neoplastic | The only administration code this product bills ($71.81, Medicare PFS national non-facility, 2026). |
96413 / 96415 | IV infusion administration, first hour / each additional hour | Not appropriate for Faspro. These codes belong to the infused product, Darzalex (J9145), which runs 3 to 7 hours. |
A 96413 or 96415 line on a Faspro claim is a formulation mix-up, not a coding choice — resubmit with 96401. See the billing units page for the units math.
Modifiers
JZ — required on every claim; there is no routine JW scenario for this product, because the 1,800 mg single-dose vial matches the labeled dose exactly.
Effective July 1, 2023, CMS requires the JZ modifier on all single-dose container claims when no drug is discarded. Because Darzalex Faspro’s one fixed dose (1,800 mg) exactly matches the one fixed vial size (1,800 mg), there is nothing left over to waste — append JZ to the J9144 line on every claim, on every regimen.
Modifier 25 — same-day E/M. Append modifier 25 to the same-day E/M code only if a significant, separately identifiable evaluation occurred beyond the routine pre-injection check-in, which is bundled into 96401.
TB — 340B drug pricing. Hospitals that acquire daratumumab through 340B and bill Medicare report the TB modifier, the sole 340B identifier since CMS discontinued JG on January 1, 2025.
Claim form
CMS-1500 / 837P (physician office; POS 11) field map for a J9144 claim.
| Information | CMS-1500 box | Notes |
|---|---|---|
| NDC qualifier + 11-digit NDC + UoM + qty | 24A shaded area | Format: N4 qualifier + 11-digit NDC + ML + 15 (mL drawn, 1 vial) |
| HCPCS J9144 + JZ | 24D (drug line) | 180 units, per MAC rounding |
| CPT 96401 | 24D (admin line) | One line, every regimen — never 96413 or 96415 |
| Pre-medication drug lines | 24D (separate lines) | Acetaminophen, diphenhydramine or equivalent, corticosteroid — billed on their own lines, not bundled into J9144 |
| ICD-10 | 21 | Indication-specific — see Coverage; the bare C90.0 is not billable |
| NPI | 17b / 24J / 33a | Rendering and billing provider NPI |
| TB modifier (340B sites only) | 24D | Hospital outpatient 340B claims only |
Darzalex Faspro coverage & access
CareCost’s payer-policy library does not yet cover oncology. Use the ICD-10 table below, and the payer’s own policy, for a live prior authorization.
- There is no daratumumab molecule in the Clearance corpus and no Darzalex Faspro coverage page on this site — check the payer’s own policy directly.
- A myeloma prior authorization typically asks for the diagnosis code (C90.00, C90.01, C90.02 or E85.81), the regimen and line of therapy, and confirmation that pre-medication was given.
ICD-10 codes by indication
Verified against the NLM Clinical Table Search Service, 2026-09-19. The bare C90.0 is a category, not billable.
| Indication | ICD-10 | Notes |
|---|---|---|
| Multiple myeloma, not having achieved remission | C90.00 | The reference patient used throughout this cluster |
| Multiple myeloma, in remission | C90.01 | |
| Multiple myeloma, in relapse | C90.02 | |
| Light chain (AL) amyloidosis | E85.81 | With bortezomib, cyclophosphamide and dexamethasone |
Bare C90.0 is not billable. Submit C90.00, C90.01 or C90.02 depending on remission status.
Full Medicare local and national coverage policies: CMS Medicare Coverage Database →
Current Darzalex Faspro pricing
Medicare ASP+6%: $57.973 / 10 mg · $10,435.14 / 1,800 mg. Add the $71.81 administration allowance for 96401 and the claim totals $10,506.95 before the sequester.
Sequestration reduces Medicare’s 80% share by 2%. Commercial plans pay a contracted rate that differs by payer and state; 37 of 37 payer price files in this site’s commercial rate data carry a J9144 rate, with an Aetna all-states median of $57.08 per 10 mg unit.
23 doses a year (first year on the 4-week schedule: weekly for 8 weeks, every 2 weeks to week 24, then every 4 weeks) at $10,506.95 per dose — drug plus 96401 administration — total $241,659.85 before the sequester. That is the first-year drug-plus-administration total for a patient on the reference 4-week schedule, before benefits or assistance; a patient on the same schedule the year after has 13 doses, not 23.
Patient cost
What a patient owes on one visit comes down to the payer’s allowed rate, whatever remains of the Part B deductible ($283 in 2026), the plan’s benefit design, and any assistance applied against the balance. At 20% coinsurance with the deductible already met, a Medicare patient’s share of one dose is $2,083.13; across 23 doses in year one that is $47,911.99 before any Medigap coverage.
Calculate a Darzalex Faspro patient estimate →
Copay & financial assistance
Janssen’s CarePath / withMe Savings Program brings a commercially insured patient’s cost for the drug down to as little as $5 per dose. A calendar-year program maximum applies, but Janssen does not publish the amount; the program covers the drug only, not the $71.81 injection or the pre-medications. Medicare, Medicaid, TRICARE, VA and government plans are excluded.
uninsured patients, patients whose coverage falls short, some commercially insured patients who meet the program's rules and some Medicare patients who meet the program's rules have a separate route: the Johnson & Johnson Patient Assistance Program ships free drug to the provider for qualifying patients, renewable annually.
Common Darzalex Faspro denials & fixes
| Denial reason | Common cause | Fix |
|---|---|---|
| 1,800 units billed | The 1,800 mg dose entered directly as units instead of divided by the 10 mg unit size | Resubmit with 180 units — J9144 bills 1 unit per 10 mg, not per mg. |
| 96413 billed on an injection | Infusion administration code applied to a subcutaneous product out of habit | Resubmit with 96401 — Faspro is never infused. 96413/96415 belong to IV Darzalex (J9145). |
| Bare C90.0 submitted | Parent ICD-10 code used instead of a billable subtype | Resubmit with C90.00, C90.01 or C90.02 depending on remission status. |
| Claim missing pre-medication lines | Acetaminophen, diphenhydramine (or equivalent) and corticosteroid not billed as their own lines | Resubmit with the pre-medication lines present — the label requires pre-medication before every dose. |
| Medicare patient referred to the copay card | Front desk applies the commercial CarePath savings card to a Medicare patient | Federal health-care program patients are excluded from the manufacturer copay program by law; route them to the J&J Patient Assistance Foundation or a foundation fund instead. |
| J9145 billed on a Faspro dose | Encounter note does not clearly state subcutaneous vs. infused administration | Confirm the formulation in the note; the unit count and administration code both differ between J9144 and J9145. |
Frequently asked questions
What is the HCPCS code for Darzalex Faspro?
J9144. It bills 1 unit per 10 mg, so the labeled 1,800 mg dose is 180 units — never 1,800. That single drug line allows $10,435.14; add the 96401 administration line and the reference visit totals $10,506.95.
What is the dosing for daratumumab and hyaluronidase-fihj by indication?
Every dose is the same 1,800 mg injection; what changes by regimen is the schedule, not the dose or the units:
- Multiple myeloma on a 4-week regimen or monotherapy = 1,800 mg weekly for weeks 1 to 8 (8 doses), every 2 weeks for weeks 9 to 24 (8 doses), then every 4 weeks from week 25 until disease progression
- Multiple myeloma on VMP = 1,800 mg weekly for weeks 1 to 6 (6 doses), every 3 weeks for weeks 7 to 54 (16 doses), then every 4 weeks from week 55 until disease progression
- Multiple myeloma, transplant-eligible (VTd or VRd) = Induction: 1,800 mg weekly for weeks 1 to 8 (8 doses), every 2 weeks for weeks 9 to 16 (4 doses); stop for high-dose chemotherapy and transplant; consolidation: every 2 weeks from re-initiation (4 doses); then every 4 weeks maintenance where the regimen continues
- Multiple myeloma on a 3-week regimen = With bortezomib and dexamethasone: 1,800 mg weekly for weeks 1 to 9 (9 doses), every 3 weeks for weeks 10 to 24 (5 doses), then every 4 weeks; with bortezomib, lenalidomide and dexamethasone: weekly for weeks 1 to 6 (6 doses), every 3 weeks for weeks 7 to 24 (6 doses), then every 4 weeks
- High-risk smoldering myeloma = 1,800 mg weekly for weeks 1 to 8 (8 doses), every 2 weeks for weeks 9 to 24 (8 doses), then every 4 weeks until a diagnosis of multiple myeloma or a maximum of 39 cycles
- AL amyloidosis on D-VCd = 1,800 mg weekly for weeks 1 to 8 (8 doses), every 2 weeks for weeks 9 to 24 (8 doses), then every 4 weeks from week 25 until disease progression or a maximum of 2 years
The dosing record above carries the full text of each schedule; the calculator on the billing units page prices one dose at a time, on any of them.
Which administration code applies to Darzalex Faspro, 96401 or 96413?
96401 ($71.81) — chemotherapy administration, subcutaneous, over about 3 to 5 minutes. 96413 and 96415 do not apply to this product; those codes belong to the infused product, Darzalex (J9145), which runs 3 to 7 hours.
Why does a Darzalex Faspro visit cost more than an IV Darzalex visit, and when does that flip?
Below about 85 kg, Faspro costs more per visit than IV Darzalex; above it, Faspro costs less — either way for a 5-minute injection in place of a 3-to-7-hour infusion. See the full breakdown on the cost page.
What ICD-10 code covers Darzalex Faspro?
Not the bare C90.0 — it is a category, not a billable code. Multiple myeloma not having achieved remission uses C90.00, in remission uses C90.01, in relapse uses C90.02. Light chain (AL) amyloidosis uses E85.81.
Is there copay assistance for Darzalex Faspro?
Janssen’s CarePath / withMe Savings Program covers commercially insured patients down to as little as $5 per dose for the drug only; a calendar-year program cap applies but Janssen does not publish the amount. Medicare, Medicaid, TRICARE, VA and government plans are excluded — a Medicare patient’s 20% share of one visit is $2,083.13.
Sources
- AAPC — HCPCS J9144 (Darzalex Faspro)
- AAPC — HCPCS J9145 (Darzalex)
- DailyMed — Darzalex Faspro prescribing information
- NLM Clinical Table Search Service — ICD-10-CM (verified 2026-09-19)
- CMS — Medicare Part B Drug ASP Pricing File
- CMS — HCPCS quarterly update file
- CMS — JW / JZ modifier guidance
- CMS Medicare Coverage Database
- jnjwithme.com — Darzalex CarePath savings support
- Johnson & Johnson Patient Assistance Program
Dataset dates: pricing Q4 2026 · assistance Sep 2026.
Reviewed September 19, 2026 by Erin Rose, CareCost Estimate founder. Methodology →